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Purpose: The objective of this study was to determine
whether the progressive increase of metabolic syndrome (MetS)
score, the number of components of MetS, is correlated
significantly with increasing pulse pressure (PP). Materials and
Methods: 4,034 subjects were enrolled from the Cardiovascular
Genome Center of Yonsei University (M: F= 2344: 1690, 55.2
±10.5). Most of the study population were recruited from
hypertension clinics, controlled with medications according to
JNC7 guidelines. The Asian modified criteria of MetS were
applied and MetS score was estimated. The HOMA index for
insulin resistance, cholesterol profiles, and anthropometric
measurements were assessed. Results: Among 4034 participants,
1690 (41.9%) were classified as MetS. Progressive increase in
PP was demonstrated for increasing components of the MetS
score. Multiple linear regression analysis with PP as the
dependent variable showed that age (β = 0.311, p < 0.001),
MetS score (β = 0.226, p < 0.001), male gender (β= -0.093, p
< 0.001) and HOMA index IR (β = 0.033, p = 0.03) are
significantly associated with PP (R
2 = 0.207, p < 0.001).
Conclusion: The present results from this study demonstrate
that increasing MetS score is an independent determinant of
increasing PP. The results also demonstrate the independent
role of MetS in increasing arterial stiffness and PP.
Key Words: Metabolic syndrome, pulse pressure, arterial
stiffness, metabolic syndrome scores
INTRODUCTION
The pulse pressure (PP), the difference between
systolic blood pressure (SBP) and diastolic blood
pressure (DBP), is known to be an important
predictor of cardiovascular and cerebrovascular
mortality in both hypertensive and normotensive
populations.
1-3
PP is determined by ventricular interaction with
the elastic properties of the large arteries and the
magnitude of wave reflection.
1,2,4 Therefore, the
increase in PP is determined primarily by the
increase in large arterial stiffness.
3 Recent epide-
miologic studies have demonstrated that the
increase in PP is independently associated with
adverse cardiovascular events.
1-3 Therefore, clinical
determinants associated with increasing PP may
have clinical significance.
Studies have shown that obesity and the
presence of MetS are associated with increasing
arterial stiffness.
5-9 Endothelial dysfunction, in-
sulin resistance, atherogenic alterations, neurohor-
monal abnormalities and hypercoagulability are
some of the factors that contribute to the increased
arterial stiffness in MetS.
5
Therefore, the objective of this study was to
determine whether the progressive increase in
MetS score, the number of components of
metabolic syndrome, is significantly correlated
with increase in PP.
MATERIALS AND METHODS
Patient population
The study group consisted of 4,034 subjects who
were enrolled at the Yonsei Cardiovascular
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Genome center (men: 2,344. women: 1,690. mean
age: 55.2 ± 10.5). The Cardiovascular Genome
Center is a Korean government-sponsored research
project, whose objective is to determine the
genetic factors that are associated with the
development of cardiovascular disease in a large
prospective Korean cohort. Most of the study
populations were recruited from the hypertension
outpatient clinic, and their blood pressure was
controlled with medications according to JNC7
guidelines.
10 The rest of subjects were composed
of populations who presented for a routine health
status check up at Yonsei Cardiovascular Center.
The blood pressure of hypertension patients was
presented as normal subjects because of proper
medications. Our database contained information
about all the constituents of the MetS, and bio-
chemical risk factors for coronary artery disease
(CAD). Subjects were asked to refrain from per-
forming strenuous exercise or drinking alcoholic
beverages 24 hours before the laboratory test.
They were also instructed to avoid eating or
drinking anything during the test except water.
Written informed consent was obtained from all
subjects, and the protocol was approved by the
Institutional Review Board of Yonsei University
College of Medicine.
Blood collection and assessment of insulin resistance
Blood samples were taken from the forearm
after at least 12 hours of fasting and collected into
EDTA-treated and plain tubes. The serum glucose
levels were determined by using the enzymatic
method (Hitach 7600 - 110, Hitachi Co., Tokyo,
Japan), and the insulin concentration with an
immunoradiometric assay (Biosource, Nivelles,
Belgium) with intra- and inter-assay coefficients of
variation of 2.1 - 4.5% and 4.7 - 12.2%, respectively.
The status of insulin resistance was measured
using the homeostasis model assessment of
insulin resistance index (HOMA index) with the
following formula;
The serum apolipoprotein A1 and B were deter-
mined by using Immuno-turbidometric analyzer
at 340 nm with a specific antiserum (Cobas Integra
Roche, USA, Rotkreuz, Switzerland).
The analysis of total cholesterol and trigly-
cerides was based on an enzymatic method
(Hitachi 7600 - 110, Hitachi Co., Tokyo, Japan).
After precipitation of serum chylomicron, low
density lipoprotein-cholesterol (LDL-C), and very
low density lipoprotein (VLDL) with dextran
sulfate-magnesium, and high density lipoprotein-
cholesterol (HDL-C) remaining in the supernatant
fluid was measured by using an enzymatic
method (Hitachi 7600-110, Hitachi Co., Tokyo,
Japan). The LDL-C level was calculated using the
Friedewald formula with serum triglyceride
concentrations < 4.52 mol/L (400 mg/dL).
11
Anthropometric and blood pressure measurements
The body weight, waist circumferences and
height were measured in the morning. Body mass
index (BMI) was calculated by dividing body
weight (in kg) by height
2 (in m). Blood pressure
was read from the left arm while subjects remained
seated. Readings of SBP and DBP were taken in
the supported left arm of the seated subject after
5 minutes of quiet rest, with a mercury column
sphygmomanometer with cuff-size adjustment
based on arm circumference. Baseline of each SBP
and DBP each was average of 3 separate measure-
ments taken by the examining physician.
Classification of metabolic status (modified NCEP
criteria for Asian)
The National Cholesterol Education Program
(NCEP) Adult Treatment Panel III (ATP III) guide-
lines
12,13 classify individuals as having the MetS if
they possess three or more of the following
criteria:
Central obesity: The World Health Organization (WHO)
has recognized the disproportionate contribution of
obesity to the development of cardiovascular risk factors
in Asians and has provisionally lowered the classifica-
tion of central obesity to > 80 or > 90 cm in females and
males
High blood pressure: If patient’s systolic and/or diastolic
blood pressures were 130/85 mmHg or patients wereIncrease of Metabolic Syndrome Score is an Independent Determinant of Increasing Pulse Pressure
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Statistical analysis
Values were expressed as mean ± SD. Statistical
analysis was performed with SPSS version 13.0 for
WINDOWS (SPSS Inc, Chicago, IL, USA) for
descriptive statistics. Linear regression analysis
was performed using the variables significant in
bivariate analysis as the candidate variables and
PP as a dependent variable.
In model 1, the MetS score (the number of
components) was entered along with age, gender,
smoking habits, and LDL cholesterol. In model 2,
the MetS score was entered with age, gender,
smoking habits, LDL cholesterol, and HOMA
index. A two-tailed value of p < 0.05 was con-
sidered statistically significant.
RESULTS
Clinical characteristics in relation to MetS score
The study population consisted of 4,034 subjects
(men: 2,344. women: 1,690. mean age: 55.2 ± 10.5).
Table 1 describes the general clinical features of
subjects included in the study and the distribution
of subjects with a 0 to 5 MetS score [MetS score
receiving blood pressure lowering drugs.
Hyperglycemia: Fasting plasma glucose 6.1 mmol/L
(110mg/dL) or patients were receiving glucose lowering
drugs.
Low HDL-cholesterol (HDL-C): Fasting HDL-C < 1.04
or 1.29 mmol/L (40 or 50 mg/dL) in males and females,
respectively.
Hypertriglyceridemia: Fasting plasma triglycerides
1.69 mmol/L (150 mg/dL).
Table 1. Clinical Characteristics of Subjects in Relation to MetS Score
Number of components of metabolic syndrome (MetS score) Total
0 (n = 525) 1 (n = 833) 2 (n = 986) 3 (n = 968) 4 (n = 572) 5 (n = 150) (n = 4034)
Age* (yrs) 52.6 ± 10.1 53.3 ± 10.7 55.3 ± 10.3 56.4 ± 10.2 57.5 ± 10.5 58.8 ± 9.3 55.2 ± 10.5
Hypertension* 0 (0%) 277 (33.3%) 463 (47.0%) 572 (59.1%) 373 (65.2%) 80 (53.3%) 1765 (43.8%)
Smoking (%) 175 (33.5%) 175 (21.1%) 183 (18.6%) 179 (18.5%) 88 (15.4%) 23 (15.3%) 823 (20.4%)
Waist* (cm) 78.3 ± 6.4 81.5 ± 7.3 86.7 ± 7.7 89.8 ± 7.9 92.8 ± 7.2 93.9 ± 6.7 86.4 ± 8.9
BMI (Kg/m
2) 22.1 ± 2.4 23.1 ± 2.5 24.5 ± 2.7 25.5 ± 2.8 26.2 ± 2.8 26.7 ± 2.8 24.5 ± 3.0
SBP* (mmHg) 108.9 ± 9.6 118.9 ± 17.0 124.7 ± 17.9 128.0 ± 18.8 131.8 ± 18.4 132.3 ± 18.9 123.5 ± 18.6
DBP* (mmHg) 72.0 ± 7.4 76.9 ± 10.8 79.5 ± 10.7 80.2 ± 10.9 81.3 ± 11.1 80.0 ± 10.3 78.4 ± 10.8
PP* (mmHg) 36.8 ± 7.6 42.0 ± 12.1 45.2 ± 12.8 47.8 ± 14.2 50.5 ± 14.3 52.3 ± 16.9 45.1 ± 13.6
TG* (mg/dL) 89.4 ± 28.7 109.2 ± 60.3 135.9 ± 74.1 178.8 ± 103.8 222.1 ± 93.2 295.5 ± 234.9 152.8 ± 103.1
LDL-C (mg/dL) 118.2 ± 31.1 120.2 ± 32.1 122.9 ± 35.2 122.4 ± 37.3 121.6 ± 39.4 123.1 ± 43.0 121.4 ± 35.5
HDL-C* (mg/dL) 54.1 ± 10.5 50.7 ± 11.6 45.4 ± 11.3 40.8 ± 10.0 37.4 ± 8.7 34.7 ± 6.6 45.0 ± 12.0
TG/HDL-C* 1.73 ± 0.69 2.29 ± 1.41 3.26 ± 2.21 4.69 ± 3.22 6.40 ± 3.65 9.04 ± 8.02 3.86 ± 3.42
ApoA1* (mg/dL) 143.3 ± 20.6 140.5 ± 23.9 133.7 ± 25.2 128.3 ± 24.3 125.9 ± 20.9 123.4 ± 18.6 132.4 ± 24.2
ApoB* (mg/dL) 76.8 ± 20.1 80.4 ± 20.7 86.9 ± 22.3 92.9 ± 22.7 97.5 ± 24.1 101.8 ± 27.0 89.0 ± 23.5
ApoB/apoA1* 0.55 ± 0.15 0.59 ± 0.17 0.67 ± 0.20 0.74 ± 0.20 0.79 ± 0.21 0.83 ± 0.23 0.70 ± 0.21
Fasting glc* (mg/dL) 83.6 ± 8.3 85.9 ± 12.0 89.4 ± 17.2 94.1 ± 24.1 101.1 ± 28.9 142.1 ± 52.4 92.7 ± 24.4
Insulin* ( IU/mL) μ 6.41 ± 5.88 7.59 ± 5.18 8.43 ± 4.34 9.72 ± 5.46 11.59 ± 7.51 14.29 ± 10.78 8.97 ± 6.13
HOMA index* 1.33 ± 1.27 1.62 ± 1.15 1.86 ± 1.01 2.29 ± 1.61 2.99 ± 2.85 5.26 ± 5.43 2.13 ± 2.06
Statin (%) 28 (5.3%) 118 (14.2%) 170 (14.2%) 214 (22.1%) 132 (23.1%) 46 (30.7%) 708 (17.6%)
Fibrates (%) 0 (0%) 10 (1.2%) 19 (1.9%) 26 (2.7%) 13 (2.3%) 10 (6.7%) 78 (1.9%)
*p value < 0.05 between groups.
BMI, body mass index; SBP, systolic blood pressure; DBP, diastolic blood pressure; PP, pulse pressure; TG, triglycerides; LDL-C,
LDL-cholesterol; HDL-C, HDL-cholesterol; apoA1, apolipoproteinA1; apoB, apolipoproteinB; fasting glc, fasting glucose.Jae-Youn Moon, et al.
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0 (n = 525), 1 (n = 833), 2 (n = 986), 3 (n = 968), 4
(n = 572), 5 (n = 150)]. As expected, the values of
all of the anthropometric, metabolic, serum lipo-
protein and marker of insulin resistance variables,
except LDL cholesterol levels, were significantly
different between the subjects with different MetS
scores. Subjects with increasing MetS scores were
associated with an increase in age, waist line, BMI,
SBP, DBP, TG, apoB, fasting glucose, insulin, and
HOMA index. A clear relation was evident
between the MetS score and the degree of insulin
resistance and hyperglycemia.
As MetS score increased, so did HOMA index,
which is a marker of increased insulin resistance.
As the number of components of the MetS rose,
the prevalence of hypertension also increased. No
difference was noted in the serum levels of LDL
cholesterol and the prevalence of current smokers.
The prevalence of NCEP Asian modified MetS (
3 metabolic components) was 41.9% (men: 35.5%,
women: 50.8%) in the study group. PP was dif-
ferent between the subjects with and without
MetS (without MetS: 42.2 ± 12.0 mmHg vs with
MetS: 49.1 ± 14.6 mmHg, p < 0.001). The prevalence
of MetS according to age group is shown in Table
2.
Effects of MetS score on pulse pressure
Fig. 1 shows the significant difference in the
level of PP for subjects with different MetS score
(Score 0: 36.8 ± 7.6 mmHg, Score 1: 42.0 ± 12.1
mmHg, Score 2: 45.2 ± 12.8 mmHg, Score 3: 47.8 ±
14.2 mmHg, Score 4: 50.5 ± 14.3 mmHg, Score 5:
52.3 ± 16.9 mmHg, p < 0.001 by one-way ANOVA
analysis). When the subjects were divided into 5
groups according to age and MetS score, PP
showed a progressive increase as the MetS score
increased within each age group (Fig. 2). The
slope of the elevation showed steep increase in the
patients over the age of 50. Also, the HOMA index
demonstrated a pattern of increase according to
increasing PP in each age groups as well (Fig. 3).
After adjustment for age and hypertension, insulin
resistance, which was measured by HOMA index,
was also correlated with PP (correlation coefficient
= 0.074, p < 0.01). We investigated whether in-
creased MetS scores were independently associated
with an increase in PP. Linear regression was
performed using the variables significant in
bivariate analysis as the candidate variables and
PP as a dependent variable, and we found asso-
ciations of MetS score with PP while controlling
for classical cardiovascular risk factors (smoking,
age, gender, LDL-C). Cardiovascular risk factors
that are components of MetS, such as the presence
of hypertension, triglycerides, HDL and obesity,
Table 2. Prevalence of Metabolic Syndrome (Total and Women Group)
30 - 39 yrs
(n = 299)
40 - 49 yrs
(n = 896)
50 - 59 yrs
(n = 1348)
60 - 69 yrs
(n = 299)
70 - 79 yrs
(n = 299)
Total
Men
(n = 2,344)
60/165
(36.4%)
206/563
(36.6%)
265/777
(34.1%)
249/716
(34.8%)
51/123
(41.4%)
831/2344
(35.5%)
Women
(n = 1,690)
31/134
(23.1%)
106/333
(31.8%)
300/571
(52.5%)
296/469
(63.1%)
126/183
(68.9%)
859/1690
(50.8%)
Total 91/299
(30.4%)
312/896
(34.8%)
565/1348
(41.9%)
545/1185
(46.0%)
177/306
(57.8%)
1,690/4,034
(41.9%)
Fig. 1. Difference of pulse pressure in relation to metabolic
syndrome score (Score 0: 36.8 ± 7.6; Score 1: 42.0 ± 12.1;
Score 2: 45.2 ± 12.8; Score 3: 47.8 ± 14.2; Score 4: 50.5 ± 14.3;
Score 5: 52.3 ± 16.9).Increase of Metabolic Syndrome Score is an Independent Determinant of Increasing Pulse Pressure
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were not entered in the analysis due to colline-
arity.
When age, gender, smoking history, serum
LDL-C, MetS score, and HOMA index were entered
into the model, the independent predictors of PP
were age (β = 0.311, p < 0.001), MetS score (β =
0.226, p < 0.001), male gender (β = - 0.093, p< 0.001)
and HOMA index (β = 0.033, p = 0.03) with a
model R
2 = 0.207 (p < 0.001)(Table 3).
DISCUSSION
The main finding from this study is that an
increase in MetS score is correlated with an
increase in PP. Furthermore, we found that MetS
score itself was an independent predictor of
increase in PP, and that an increasing degree of
MetS score is associated with an increase in the
parameter of insulin resistance, such as HOMA
index.
Fig. 2. Difference of pulse pressure in relation to metabolic syndrome score (in age groups).
Fig. 3. Difference of pulse pressure between HOMA 4 quartiles.Jae-Youn Moon, et al.
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MetS and increasing arterial stiffness
MetS is recognized as a cluster of cardiovas-
cular risk factors that frequently coincides with
insulin resistance and hyperglycemia. Previous
studies showed that obesity and the presence of
MetS are associated with increasing arterial stif-
fness.
5-9 Moreover, the independent association
between vascular structure with function and each
component of MetS has previously been reported.
8
In the present study, regression analysis revealed
that an increase of MetS score was proportionately
related to an increase in PP, demonstrating that
increasing component of MetS is a determinant of
increasing PP, irrespective of age. Because tradi-
tional risk factors of cardiovascular disease are
known to be associated with increasing degree of
arteriosclerosis, the clustering of risk factors in
patients with MetS may be one of the important
factors for the elevation in arterial stiffness and
subsequent increase in PP.
14-16 However, the effect
of MetS is more than the sum of its parts, with
each components acting synergistically in the
development of cardiovascular disesase.
17,18 In a
cross sectional analysis of the Baltimore Longitudi-
nal Study of Aging (BLSA), the clustering of
components of MetS exerted a synergistic effect
on vascular stiffness that was more than the effect
of individual components of MetS.
8 MetS is
associated with an increase in sympathetic and
neurohormonal activation, endothelial dysfunction
and increasing degree of insulin resistance which
may act in concert to increase arterial stiffness and
PP.
5,19,20
Vascular inflammation is also an important
determinant of increasing arterial stiffness with an
increase in serum high sensitivity C-reactive
protein (hsCRP) that is associated with increase in
pulse wave velocity.
21 Inflammation plays a key
role in the development of complications in
metabolic syndrome, and hsCRP is known to be
significantly correlated with each component of
metabolic syndrome as well as degree of insulin
resistance.
22-24 Therefore, an increasing degree of
vascular inflammation may be important in
increasing arterial stiffness and PP in patients
with MetS.
Mechanisms of correlations between insulin
resistance and arterial stiffness
An interesting finding from this study is the
progressive increase in insulin resistance that is
associated with increase in PP. This finding was
Table 3. Multiple Regression Models Evaluating the Independent Determinants of PP
Model 1: R
2 = 0.206, p < 0.001
B Beta 95% CI for Unstandardized B p value
Age 0.401 0.310 0.365 ~ 0.438 < 0.001
MetS score 2.396 0.238 2.105 ~ 2.678 < 0.001
Men - 2.525 - 0.092 - 3.668 ~ - 1.383 < 0.001
LDL cholesterol level 0.010 0.027 - 0.001 ~ 0.021 0.063
Smoking habits - 0.775 - 0.029 - 1.883 ~ 0.333 0.170
Model 2 (Model A + HOMA index): R
2 = 0.207, p < 0.001
B Beta 95% CI for Unstandardized B p value
Age 0.402 0.311 0.365 ~ 0.438 < 0.001
MetS score 2.282 0.226 1.973 ~ 2.590 < 0.001
Men - 2.557 - 0.093 - 3.699 ~ - 1.415 < 0.001
HOMA index 0.231 0.033 0.023 ~ 0.440 0.030
LDL cholesterol level 0.010 0.026 - 0.001 ~ 0.021 0.077
Smoking habits - 0.790 - 0.029 - 1.897 ~ 0.317 0.162Increase of Metabolic Syndrome Score is an Independent Determinant of Increasing Pulse Pressure
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demonstrated in all age groups, except for the
subgroup of patients over 70 years. Insulin resist-
ance is known to be associated with increasing
arterial stiffness.
25 Although the mechanism
underlying this association is not clearly defined,
insulin resistance state is associated with decreased
endothelial dependent arterial compliance.
25 Also,
insulin is known to diminish wave reflection the
effect of which is blunted in obese, insulin
resistance state,
26 and regression analysis which
HOMA index in the equation demonstrated that
insulin resistance is independently associated with
increase in PP. (Table 3, model 2) However, the
addition of HOMA index to the regression model
resulted in weak contribution of insulin resistance
to pulse pressure with an increase of R
2 from
0.206 to 0.207 (Table 3). Therefore, the clustering
of components of MetS that exerts a synergistic
effect on vascular stiffness may be more important
in increasing pulse pressure than insulin resist-
ance itself.
The prevalence of MetS in this study population
was relatively high due to the fact that the study
population consisted of a high proportion of
patients with a history of cardiovascular disease
and hypertension. Also, many patients consented
to enroll at the cardiovascular genome center due
to health concerns. Therefore, the prevalence of
MetS in our data does not reflect that of the
general population. Furthermore, blood pressure
and PP in this study were relatively low, and the
reason appeared to be that many of the patients
in the study group were being administered with
antihypertensive medications. Nevertheless, this
would not diminish the clinical impact of this
study since PP is a significant predictor for car-
diovascular risk in treated hypertensive patients
as well.
27
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